Literature DB >> 3680581

Cyclosporine kinetics in healthy volunteers.

R J Ptachcinski1, R Venkataramanan, G J Burckart, J A Gray, D H Van Thiel, A Sanghvi, J T Rosenthal.   

Abstract

The pharmacokinetics of cyclosporine was studied in five healthy male volunteers following intravenous administration. The subjects received 2.1 mg/kg of cyclosporine as a two-hour intravenous infusion. Blood samples were collected over the subsequent 48 hours. Cyclosporine was extracted from whole blood and analyzed by high-performance liquid chromatography (HPLC) and radioimmunoassay (RIA). Following the intravenous infusion of cyclosporine, the drug exhibited multicompartmental behavior. The harmonic mean distribution half-life based on HPLC data was 0.45 hours, and the harmonic mean terminal disposition half-life was 6.2 hours. The clearance of cyclosporine based on HPLC cyclosporine concentrations was 3.9 mL/min/kg, and the volume of distribution at steady state of cyclosporine was 1.23 L/kg. Cyclosporine has a shorter half-life, lower clearance, and smaller Vss in healthy persons as compared to patient populations. The differences observed in the pharmacokinetics of cyclosporine in healthy persons as compared to patient populations may be due to differences in hematocrit, lipoprotein profiles, and/or concurrent drug therapy between the groups. Cyclosporine concentrations determined by RIA were consistently higher than those determined by HPLC, resulting in a significantly higher area under the blood concentration versus time curve and lower clearance rate for cyclosporine. We conclude that: (1) kinetic parameter estimates for cyclosporine are different in healthy individuals as compared with organ-transplant recipients, and (2) the kinetic parameters for cyclosporine are different, depending on the assay technique used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680581     DOI: 10.1002/j.1552-4604.1987.tb02193.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

1.  On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers.

Authors:  J P Reymond; J L Steimer; W Niederberger
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

2.  Exposure of cyclosporin A in whole blood, cerebral spinal fluid, and brain extracellular fluid dialysate in adults with traumatic brain injury.

Authors:  Gretchen M Brophy; Anna Teresa Mazzeo; Satjit Brar; Oscar Luis Alves; Kristen Bunnell; Charlotte Gilman; Tom Karnes; Ron L Hayes; Ross Bullock
Journal:  J Neurotrauma       Date:  2013-08-02       Impact factor: 5.269

3.  Cyclosporine trough concentration monitoring in liver transplant patients.

Authors:  G J Burckart; R J Ptachcinski; R Venkataramanan; S Iwatsuki; C Esquivel; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

Review 4.  Ciclosporin use during pregnancy.

Authors:  Karolina Paziana; Magaly Del Monaco; Elyce Cardonick; Michael Moritz; Matthew Keller; Bruce Smith; Lisa Coscia; Vincent Armenti
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

Review 5.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

Review 6.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

8.  Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring.

Authors:  Sonja E Zapke; Stefan Willmann; Scott-Oliver Grebe; Kristin Menke; Petra A Thürmann; Sven Schmiedl
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.